Comparison of serum VEGF and its soluble receptor sVEGFR1 with serum cell-free DNA in patients with breast tumor

Cytokine

Volumn 44, Issue 1, 2008, Pages 65-69

  El Tarhouny, Shereen ^a,b   Seefeld, Martin ^a   Fan, Alex Xiu Cheng ^a   Hahn, Sinuhe ^a   Holzgreve, Wolfgang ^a   Zhong, Xiao Yan ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

Biomarkers; Breast cancer; Cell free DNA; VEGF; VEGFR1

Indexed keywords

DNA; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST TUMOR; CELL FREE SYSTEM; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; BREAST NEOPLASMS; DNA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 52949114526     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2008.06.008     Document Type: Article

References (29)

1. Greenlee R.T., Murray T., Bolden S., and Wingo P.A. Cancer statistics. Cancer J Clin 50 7 (2000) 33
2. Harada Y., Ogata Y., and Shirouzu K. Expression of vascular endothelial growth factor and its receptor KDR (kinase domain-containing receptor)/Flk-1 (fetal liver kinase-1) as prognostic factors in human colorectal cancer. Int J Clin Oncol 6 (2001) 221-228
3. Harris S.R., Schoeffner D.J., Yoshiji H., and Thorgeirsson U.P. Tumor growth enhancing effects of vascular endothelial growth factor are associated with increased nitric oxide synthase activity and inhibition of apoptosis in human breast carcinoma xenografts. Cancer Lett 179 (2002) 95-101
4. Mylona E., Alexandrou P., Giannopoulou I., Liapis G., Sofia M., Keramopoulos A., et al. The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor VEGFR-1 in invasive breast carcinoma. Gynaecol Oncol 1049 0629 (2007) 557-563
5. Hasan J., and Jayson G.C. VEGF antagonists. Expert Opin Biol Ther 1 (2001) 703-718
6. Cai J., Ahmad S., Jiang W.G., Huang J., Kontos C.D., Boulton M., et al. Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells. Diabetes 52 (2003) 2959-2968
7. Granato A.M., Nanni O., Falcini F., Folli S., Mosconi G., De Paola F., et al. Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: useful as diagnostic tools?. Breast Cancer Res 6 1 (2003) 38-45
8. Enjoji M., Nakamuta M., Yamaguchi K., Ohta S., Kotoh K., Fukushima M., et al. Clinical significance of serum levels of vascular endothelial growth factor and its receptor in biliary disease and carcinoma. World J Gastroenterol 11 8 (2005) 1167-1171
9. Boddy J.L., Gal S., Malone P.R., Harris A.L., and Wainscoat J.S. Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease. Clin Cancer Res 11 4 (2005) 1394-1399
10. Gautschi O., Bigosch C., Huegli B., Jermann M., Marx A., Chassé E., et al. Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 22 20 (2004) 4157-4164
11. Giacona M.B., Ruben G.C., Iczkowski K.A., Roos T.B., Porter D.M., and Sorenson G.D. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 17 1 (1998) 89-97
12. Tamkovich S.N., Cherepanova A.V., Kolesnikova E.V., Rykova E.Y., Pyshnyi D.V., Vlassov V.V., et al. Circulating DNA and DNase activity in human blood. Ann NY Acad Sci 1075 (2006) 191-196 10.1196/annals.1368.026
13. Ziegler A., Zangemeister W.U., and Stahel R.A. Circulating DNA a new diagnostic gold mine?. Cancer Treat Rev 28 (2002) 255-271
14. Umetani N., Giuliano A.E., Hiramatsu S.H., Amersi F., Nakagawa T., Martino S., et al. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol 24 (2006) 4270-4276
15. Goebel G., Zitt M., and Muller H.M. Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patient with solid neoplasia. Dis Markers 21 (2005) 105-120
16. Zhong X.Y., Ladewig A., Schmid S., Wight E., Hahn S., and Holzgreve W. Elevated level of cell-free plasma DNA is associated with breast cancer. Arch Gynecol Obstet (2007) 10.1007/s00404-007-0345
17. Zhong X.Y., Laivuori H., Livingston J.C., Ylikorkala O., Sibai B.M., Holzgreve W., et al. Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentrations in the plasma of pregnant women with preeclampsia. Am J Obstet Gynecol 184 3 (2001) 414-419
18. Caine G.J., Stonelake P.S., Lip G.Y., and Blann A.D. Changes in plasma vascular endothelial growth factor angiopoietins and their receptors following surgery for breast cancer reference. Cancer Lett 248 1 (2007) 131-136
19. Anker P. Quantitative aspect of plasma and serum DNA in cancer patients. Ann NY Acad Sci 906 (2000) 5-7
20. Fine B.A., Valente P.T., Feinstein G.I., and Dey T. VEGF. Flt-1 and KDR/flk-1 as prognostic indicators in endometrial carcinoma. Gynecol Oncol 76 (2000) 33-39
21. Toi M., Bando H., Ogawa T., Muta M., Hornig C., and Weich H.A. Significance of vascular endothelial growth factor (VEGF) soluble VEGF receptor-1 relationship in breast cancer. Int J Cancer 98 (2002) 14-18
22. Yoshiji H., Harris S.R., and Thorgeirsson U.P. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 57 (1997) 3928
23. Kendall R.L., Wang G., and Thomas K.A. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226 (1996) 324-328
24. Robak E., Jedrzejewska A.S., and Robak T. Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patient with systemic lupus erythematosus. Mediators Inflamm 12 5 (2003) 293-298
25. Gal S., Fidler C., Lo Y.M., Taylor M., Han C., Moore J., et al. Quantification of circulating DNA in the serum of breast cancer patients by real-time PCR. Br J Cancer 90 (2004) 1211-1215
26. Tamkovich S.N., Laktionov P.P., Rykova E.Y., and Vlassov V.V. Simple and rapid procedure suitable for quantitative isolation of low and high molecular weight extracellular nucleic acids. Nucleosides Nucleotides Nucleic Acids 23 (2004) 873-877
27. Farias E., Ranuncolo S., Cresta C., Specterman S., Armanasco E., Varela M., et al. Plasma metalloproteinase is enhanced in the euglobulin fraction of breast and lung cancer patients. Int J Cancer 89 (2000) 389-394
28. Skvortsova T.E., Rykova E.Y., Tamkovich S.N., Bryzgunova O.E., Starikov A.V., Kuznetsova N.P., et al. Cell-free and cell-bound circulating DNA in breast tumors: DNA quantification and analysis of tumor related gene methylation. Br J Cancer 94 (2006) 1492-1495
29. Chun F.K., Muller I., Lange I., Friedrich M.G., Erbersdobler A., Karakiewicz P.I., et al. Circulating tumor-associated plasma DNA represents an independent and informative predictor of prostate cancer. BJU Int 98 (2006) 544-548